{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arnuity+Ellipta",
    "query": {
      "intervention": "Arnuity Ellipta"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arnuity+Ellipta&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T09:58:44.175Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02924688",
      "title": "A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FF/UMEC/VI (100/31.25/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI (100/62.5/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI (200/31.25/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI (200/62.5/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/VI (100/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/VI (200/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone/salmeterol (FSC)",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA DPI",
          "type": "DEVICE"
        },
        {
          "name": "DISKUS DPI",
          "type": "DEVICE"
        },
        {
          "name": "METERED-DOSE INHALER (MDI)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2436,
      "start_date": "2016-10-13",
      "completion_date": "2019-02-22",
      "has_results": true,
      "last_update_posted_date": "2021-03-26",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 99,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02924688"
    },
    {
      "nct_id": "NCT03002389",
      "title": "Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Anoro Ellipta",
          "type": "DRUG"
        },
        {
          "name": "Arnuity Ellipta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 95,
      "start_date": "2017-11-05",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 1,
      "location_summary": "Keswick, Virginia",
      "locations": [
        {
          "city": "Keswick",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03002389"
    },
    {
      "nct_id": "NCT02135718",
      "title": "ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "ELLIPTA inhaler",
          "type": "DEVICE"
        },
        {
          "name": "Placebo Inhalation Aerosol (MDI)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 288,
      "start_date": "2014-06",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2016-06-08",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 15,
      "location_summary": "Huntington Beach, California • Newport Beach, California • Vista, California + 12 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02135718"
    },
    {
      "nct_id": "NCT02301975",
      "title": "An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powders via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powder via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1526,
      "start_date": "2015-03-01",
      "completion_date": "2016-11-25",
      "has_results": true,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 34,
      "location_summary": "Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02301975"
    },
    {
      "nct_id": "NCT03949842",
      "title": "Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone furoate/umeclidinium/vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-27",
      "completion_date": "2022-11-30",
      "has_results": false,
      "last_update_posted_date": "2020-04-22",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 3,
      "location_summary": "Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah",
      "locations": [
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Layton",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03949842"
    },
    {
      "nct_id": "NCT05757102",
      "title": "A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA",
          "type": "DEVICE"
        },
        {
          "name": "FF/VI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 292,
      "start_date": "2023-04-25",
      "completion_date": "2027-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05757102"
    },
    {
      "nct_id": "NCT03478683",
      "title": "A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "budesonide/formoterol",
          "type": "DRUG"
        },
        {
          "name": "albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match budesonide/formoterol",
          "type": "DRUG"
        },
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "placebo to match tiotropium",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA",
          "type": "DEVICE"
        },
        {
          "name": "MDI",
          "type": "DEVICE"
        },
        {
          "name": "HandiHaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 729,
      "start_date": "2018-06-25",
      "completion_date": "2019-03-14",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 40,
      "location_summary": "Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more",
      "locations": [
        {
          "city": "Gold River",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeBary",
          "state": "Florida"
        },
        {
          "city": "Edgewater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03478683"
    },
    {
      "nct_id": "NCT02105974",
      "title": "Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1621,
      "start_date": "2014-04-07",
      "completion_date": "2015-07-08",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 17,
      "location_summary": "Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Sunset",
          "state": "Louisiana"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02105974"
    },
    {
      "nct_id": "NCT03012061",
      "title": "Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "UMEC",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 425,
      "start_date": "2017-01-25",
      "completion_date": "2018-05-30",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 19,
      "location_summary": "Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Natchitoches",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03012061"
    },
    {
      "nct_id": "NCT06372496",
      "title": "Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate",
          "type": "DRUG"
        },
        {
          "name": "Inhaled corticosteroids/long-acting beta-2 agonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1366,
      "start_date": "2024-04-16",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-09-03T09:58:44.175Z",
      "location_count": 36,
      "location_summary": "Centreville, Alabama • Little Rock, Arkansas • Newport Beach, California + 30 more",
      "locations": [
        {
          "city": "Centreville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06372496"
    }
  ]
}